aTYR PHARMA INC (ATYR): who owns it and who trades it
As of Nov 16, 2026, ATYR insiders reported 3 open-market sales worth $6.3K and 1 purchase worth $50K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sanjay Shukla (CEO), with $3.7K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling ATYR Pharma
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ATYR
89 funds and institutions reported ATYR shares worth $24.2M at the end of Q2 2026, about 41% of the company. The largest holder is Federated Hermes, Inc. with 8.7%.
Funds and institutions (13F) 41%Everyone else 59%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Federated Hermes, Inc. | 8.51M | 8.68% | $5.1M | -19% |
| Vanguard Capital Management LLC | 3.81M | 3.88% | $2.3M | -0% |
| Kalehua Capital Management LLC | 3.58M | 3.65% | $2.1M | – |
| Gsa Capital Partners LLP | 3.45M | 3.52% | $2.1M | +105% |
| AQR Capital Management LLC | 2.61M | 2.66% | $1.6M | +426% |
| FMR LLC (Fidelity) | 2.47M | 2.52% | $1.5M | -83% |
| BlackRock, Inc. | 1.83M | 1.86% | $1.1M | -72% |
| Jane Street Group, LLC | 1.72M | 1.76% | $1M | +3449% |
| UBS Group AG | 1.53M | 1.56% | $914K | -60% |
| Morgan Stanley | 1.34M | 1.37% | $802K | +10% |
| Two Sigma Investments, LP | 1.25M | 1.27% | $743K | +9% |
| Citadel Advisors LLC | 1.24M | 1.27% | $741K | +2522% |
| Geode Capital Management, LLC | 1.18M | 1.20% | $703K | -51% |
| Susquehanna International Group, LLP | 747,039 | 0.76% | $446K | -14% |
| Millennium Management LLC | 656,051 | 0.67% | $392K | -60% |
| Goldman Sachs Group Inc | 641,208 | 0.65% | $383K | +126% |
| Vanguard Fiduciary Trust Co | 576,125 | 0.59% | $344K | -12% |
| State Street Corp | 494,951 | 0.50% | $295K | -72% |
| Marshall Wace, LLP | 368,120 | 0.38% | $221K | +167% |
| XTX Topco Ltd | 226,678 | 0.23% | $135K | +103% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ATYR insiders reported $50K of open-market purchases and $6.3K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 27, 2026 | Paul Schimmel | Director | Purchase | 100,000 | $0.50 | $50K | Form 4 |
| Feb 4, 2026 | Sanjay Shukla | CEO | Sale | 3,745 | $0.98 | $3.7K | Form 4 |
| Feb 4, 2026 | Jill Marie Broadfoot | CFO | Sale | 1,558 | $0.98 | $1.5K | Form 4 |
| Feb 4, 2026 | Nancy Denyes | General Counsel | Sale | 1,118 | $0.98 | $1.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Paul Schimmel | Director | $50K | – | May 27, 2026 |
| Sanjay Shukla | President and CEO, Director | – | $3.7K | Feb 4, 2026 |
| Jill Marie Broadfoot | Chief Financial Officer | – | $1.5K | Feb 4, 2026 |
| Nancy Denyes | General Counsel | – | $1.1K | Feb 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ATYR short interest
Low short interest. 0.3% of ATYR shares are sold short: about 1 share in 334. Over the last 12 reports the number of shares short went down 99%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 293,448 ATYR shares were sold short, 0.3% of the shares outstanding, down 97.1% from the report before. At the average daily volume of 87,073 shares, buying them all back would take about 3.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 293,448 | 0.30% | -97% | 87,073 | 3.4 |
| Oct 15, 2026 | 10.27M | 10.47% | -20% | 1.91M | 5.4 |
| Sep 30, 2026 | 12.89M | 13.14% | +21% | 13.42M | 1.0 |
| Sep 15, 2026 | 10.67M | 10.88% | +15% | 896,229 | 11.9 |
| Aug 31, 2026 | 9.28M | 9.46% | -2% | 577,421 | 16.1 |
| Aug 14, 2026 | 9.44M | 9.63% | -3% | 641,232 | 14.7 |
| Jul 31, 2026 | 9.73M | 9.92% | +18% | 826,988 | 11.8 |
| Jul 15, 2026 | 8.28M | 8.44% | -43% | 1.95M | 4.2 |
| Jun 30, 2026 | 14.51M | 14.79% | -22% | 2.86M | 5.1 |
| Jun 15, 2026 | 18.51M | 18.88% | -8% | 1.90M | 9.8 |
| May 29, 2026 | 20.19M | 20.59% | -6% | 4.03M | 5.0 |
| May 15, 2026 | 21.39M | 21.82% | +8% | 4.77M | 4.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
ATYR Pharma company events
ATYR Pharma filed 13 reports on Form 8-K in the last 12 months, 2 of them about an important change (listing). The latest was on Nov 6, 2026.
- Nov 6, 2026AnnouncementATyr Pharma, Inc. filed a prospectus supplement related to the sale of the Company’s common stock, par value $0.001 per share with the Securities and Exchange Commission pursuant to which the Company may offer and sell Common Stock having an aggregate offering price of up to $79.99 million from… Filing
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 27, 2026RulesChanged its bylaws or articles. Filing
- Oct 16, 2026VoteReported shareholder vote results. Filing
- Sep 24, 2026AnnouncementATyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease… Filing
- Aug 7, 2026ResultsReleased financial results. Filing
- Jul 31, 2026AgreementEnded an important agreement. Filing
- Jun 8, 2026ListingAs previously disclosed, on December 4, 2025, aTyr Pharma, Inc. received a deficiency notice from the listing qualifications staff of The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s… Filing
- Jun 1, 2026AnnouncementShared information with investors. Filing
- May 15, 2026ResultsReleased financial results. Filing
- May 11, 2026AnnouncementThe Company announced a regulatory and clinical update for its lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis, a major form of interstitial lung disease, following the receipt of the official meeting minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA). Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Dec 5, 2025ListingATyr Pharma, Inc. received a deficiency notice from the listing qualifications staff of The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common stock had closed below $1.00 per share… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
ATYR Pharma financials
Famous investors that hold ATYR
2 of the 50 well-known investors we track reported holding ATYR in their latest 13F filing. The largest position is Israel Englander's, worth $176K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 581,272 | $176K | 0.0% | -11% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 281,522 | $85.3K | 0.0% | +70% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ATYR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 4, 2026 | Federated Hermes, Inc. | 13G/A | 0.0% |
| Nov 4, 2026 | Federated Hermes, Inc. | 13G/A | 0.0% |
| Oct 7, 2026 | Federated Hermes, Inc. | 13G/A | 5.1% |
| Oct 7, 2026 | Federated Hermes, Inc. | 13G/A | 5.1% |
Questions about aTYR PHARMA INC (ATYR) stock
Who owns the most ATYR stock?
The largest reported owner of aTYR PHARMA INC (ATYR) is Federated Hermes, Inc., with 8.7% of the company. In total, 89 funds and institutions reported holding ATYR at the end of Q2 2026, together about 41% of the shares. See the largest owners.
Are ATYR insiders buying or selling?
In the last 12 months, ATYR insiders reported 1 open-market purchase worth $50K and 3 sales worth $6.3K. The latest trade was on May 27, 2026. See every trade.
What is the short interest in ATYR?
As of Oct 30, 2026, 293,448 ATYR shares were sold short, 0.3% of the shares outstanding, down 97.1% from the report before. At the average daily volume of 87,073 shares, buying them all back would take about 3.4 trading days (days to cover). See the history.
Which famous investors hold ATYR?
2 of the 50 well-known investors we track reported ATYR in their latest 13F filing, including Israel Englander, Jim Simons. The largest position is worth $176K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.